Meal timing may improve drug tolerance for teens with NF1 tumors

NCT ID NCT05101148

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 27 times

Summary

This study looks at how taking the drug selumetinib with a low-fat meal affects stomach side effects and drug levels in adolescents (ages 12 to under 18) with neurofibromatosis type 1 (NF1) who have inoperable plexiform neurofibromas. The goal is to find the best way to take the drug to reduce nausea, vomiting, and diarrhea while keeping it effective. About 24 participants will be enrolled to compare taking the drug on an empty stomach versus with food.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROFIBROMATOSIS TYPE 1 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Research Site

Rochester, Minnesota, 55905, United States
Research Site

Akron, Ohio, 44308, United States
Research Site

Bydgoszcz, 85-094, Poland
Research Site

Gdansk, 80-952, Poland
Research Site

Warsaw, 02-091, Poland
Research Site

Moscow, 119620, Russia
Research Site

Moscow, 125412, Russia
Research Site

Barcelona, 08950, Spain
Research Site

Madrid, 28009, Spain

Conditions

Explore the condition pages connected to this study.

NEUROFIBROMATOSIS TYPE 1